Table 1.
Potential therapeutic agents for anaplastic lymphoma kinase-driven pediatric tumors
| Agents | Drug | Company | Targets | Susceptible tumors | References |
|---|---|---|---|---|---|
| ALK inhibitors | Crizotinib | Pfizer | MET/ALK | ALCL, IMT, NB | (26) |
| CH5424802 (AF-802) | Chugai Pharmaceutical | ALK | ALCL, IMT, NB | (41) | |
| ASP3026 | Astellas Pharma | ALK | ALCL, IMT, NB | ||
| LDK378 | Novartis | ALK | ALCL, IMT, NB | ||
| AP26113 | Ariad | ALK/EGFR | ALCL, IMT, NB | (42) | |
| 2-Acyliminobenzimidazoles | Amgen | ALK | ALCL, IMT, NB | (43) | |
| X-396 | Xcovery | ALK | ALCL, IMT, NB | ||
| GSK-1838705 | GlaxoSmithKline | ALK/IGF1R | ALCL, IMT, NB | ||
| NMS-E628 | Nerviano Medical Sciences | ALK/TRK | ALCL, IMT, NB | ||
| Inhibitors to downstream targets | Dasatinib | Bristol Myers Squibb | SRC | ALCL | (44),(45) |
| Tanespimycin | Bristol Myers Squibb | HSP90 | ALCL | (46) | |
| GSK-2141795 | GlaxoSmithKline | AKT | ALCL | (47) | |
| BP-1-102 | NA | STAT3 | ALCL | (48),(49) | |
| Vaccination | NA | NA | NPM-ALK | ALCL | (50) |
AKT protein kinase B, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, HSP90 heat shock protein 90, IGF1R insulin growth factor receptor 1, IMT inflammatory myofibroblastic tumors, MET N-methyl-N′-nitro-N-nitroso-guanidine (MNNG) HOS transforming gene, NA not available, NB neuroblastoma, NPM nucleophosmin, SRC sarcoma, STAT3 signal transducer and activator 3, TRK tropomyosin-receptor kinases